Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
101.52
-0.50 (-0.49%)
At close: Oct 17, 2025, 4:00 PM EDT
101.38
-0.14 (-0.14%)
After-hours: Oct 17, 2025, 7:57 PM EDT
Cidara Therapeutics Revenue
In the year 2024, Cidara Therapeutics had annual revenue of $1.28M, down -94.52%.
Revenue (ttm)
$1.28M
Revenue Growth
-94.52%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
2.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.28M | -22.01M | -94.52% |
| Dec 31, 2023 | 23.28M | -213.00K | -0.91% |
| Dec 31, 2022 | 23.50M | -26.08M | -52.60% |
| Dec 31, 2021 | 49.57M | 37.51M | 310.81% |
| Dec 31, 2020 | 12.07M | -8.85M | -42.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CDTX News
- 5 days ago - Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 - GlobeNewsWire
- 8 days ago - Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 - GlobeNewsWire
- 9 days ago - Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention - GlobeNewsWire
- 16 days ago - Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic - GlobeNewsWire
- 23 days ago - Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations - GlobeNewsWire
- 24 days ago - Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza - GlobeNewsWire
- 4 weeks ago - Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting - GlobeNewsWire
- 5 weeks ago - Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha